Softwr

Healthcare · head to head

PathAI vs Signant Health

PathAI logo

PathAI

Healthcare

Digital pathology image management with an FDA cleared platform for primary diagnosis

From
On request
Rated
-
Full reviewWebsite
Signant Health logo

Signant Health

Healthcare

eCOA-first clinical trial platform that has grown outward into EDC, eConsent and televisits

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: PathAI aISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.; Signant Health no pricing is published, and the software licence is a minority of the real bill once instrument licensing, translations, device provisioning and services are added, so early budget estimates are routinely too low.
  • They diverge on capability: PathAI covers AISight image management, Signant Health covers eCOA and ePRO.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which PathAI and Signant Health actually diverge.

Attributes where PathAI and Signant Health differ
AttributePathAISignant Health
PlatformsWebWeb, iOS, Android

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in PathAI

  • AISight image management
  • AISight Dx
  • Scanner interoperability
  • Case and worklist management
  • AI algorithm deployment
  • Biopharmaceutical research tooling
  • LIS integration

Only in Signant Health

  • eCOA and ePRO
  • Unified platform
  • eConsent
  • Randomisation and supplies
  • TeleVisits
  • Rater training
  • Data surveillance
  • Instrument library

What people use each for

The jobs each tool is most often brought in to do.

PathAI

  • An academic medical centre going digital for primary diagnosis that needs the FDA cleared AISight Dx configuration rather than the research labelled versionnot Signant Health
  • A reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any locationnot Signant Health
  • A pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readersnot Signant Health
  • A laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewernot Signant Health

Signant Health

  • A central nervous system or psychiatry trial where the primary endpoint is a rated scale and rater consistency decides the readoutnot PathAI
  • A global study needing an outcome instrument translated and linguistically validated across a dozen languagesnot PathAI
  • A decentralised or hybrid protocol combining televisits, eConsent and at-home patient reported outcomesnot PathAI
  • A sponsor consolidating separate eCOA, eConsent and randomisation vendors onto one platform to cut reconciliation worknot PathAI

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

PathAI

  • AISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • The software licence is usually the smallest line in a digital pathology project, behind scanners, storage and network capacity, so a business case built around the software cost understates the real investment by a wide margin.
  • Whole slide images are very large, so a laboratory that does not model storage growth and retention policy from the start faces storage costs that grow faster than case volume and dominate the renewal.
  • Clinical validation is required per subspecialty rather than once for the platform, which means dermatopathology, gastrointestinal and breast each need their own concordance study and pathologist time before go live.
  • PathAI competes against pathology incumbents that also sell the scanners, and a laboratory buying an independent image management layer takes on the integration risk between scanner vendor and software vendor itself.

Signant Health

  • No pricing is published, and the software licence is a minority of the real bill once instrument licensing, translations, device provisioning and services are added, so early budget estimates are routinely too low.
  • Linguistic validation is charged per instrument per language and is on the critical path to first patient in, so adding a country late in start-up produces both a cost and a schedule hit.
  • Provisioned participant devices bring logistics, replacement, shipping and cellular connectivity obligations that persist for the life of the trial and are frequently underestimated.
  • The EDC component is newer than the eCOA heritage, so sponsors with complex data management requirements often keep an incumbent EDC and lose the single-database benefit that justifies the platform.
  • It is priced and scoped for sponsor-grade trials, which makes it a poor fit for investigator-initiated or academic studies that need outcome collection without the services layer.

Pricing, plan by plan

PathAI

On request
  • AISight$undefined/year
    • Priced by annual slide or case volume and by pathologist seats
    • AISight Dx, the clinically cleared configuration, quoted separately from research use AISight
    • Image storage priced by capacity and retention policy

Signant Health

On request
  • SmartSignals Unified Platform$undefined/year
    • Priced per study through a sales process
    • Modules selected per protocol: EDC, eCOA, randomisation, eConsent, TeleVisits
    • Instrument licensing paid to scale owners on top of platform cost

Which should you pick?

Choose PathAI if

  • You need aisight image management.
  • You also want aisight dx.
PathAI review

Choose Signant Health if

  • You need ecoa and epro.
  • You work on Web, iOS, Android.
  • You also want unified platform.
Signant Health review

Questions people ask

Is PathAI or Signant Health better?
Neither clearly leads. PathAI starts at On request and Signant Health at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, PathAI or Signant Health?
PathAI starts at On request and Signant Health at On request.
Does PathAI or Signant Health run on more platforms?
PathAI runs on Web. Signant Health runs on Web, iOS, Android.
What is PathAI best used for?
PathAI is most often used for an academic medical centre going digital for primary diagnosis that needs the fda cleared aisight dx configuration rather than the research labelled version, a reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any location, a pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readers, a laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewer. Of those, an academic medical centre going digital for primary diagnosis that needs the fda cleared aisight dx configuration rather than the research labelled version and a reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any location are not what Signant Health is typically brought in for.
What can PathAI do that Signant Health cannot?
PathAI covers AISight image management, AISight Dx, Scanner interoperability, Case and worklist management. Signant Health covers eCOA and ePRO, Unified platform, eConsent, Randomisation and supplies.

Answered from the vendors’ own pages

PathAI: What is the difference between AISight and AISight Dx?

AISight is for research use only and not for clinical diagnostic use. AISight Dx received FDA 510(k) clearance in June 2025 for primary diagnosis and is CE-IVD marked in the EEA, UK and Switzerland. Only the Dx configuration can be used to sign out cases.

Signant Health: What is Signant best at?

Electronic clinical outcome assessment, particularly rated scales in central nervous system and psychiatry trials, together with rater training and endpoint quality services.

PathAI: Can we use our existing scanners?

Yes. AISight is designed to ingest images from multiple whole slide scanner vendors, which is one of the main reasons laboratories choose an independent image management layer.

Signant Health: Is pricing published?

No. Everything is quoted per study, and instrument licences, translations and devices sit on top of the platform cost.

PathAI: Do the AI algorithms carry the same clearance as the platform?

No. The platform clearance covers image management for primary diagnosis. Individual algorithms have their own labelling, and many are research use only. Check each one separately.

Signant Health: Can I use it only for eCOA?

Yes. The modules are selected per protocol, and many sponsors take eCOA and eConsent while keeping an existing EDC.

PathAI: Is pricing published?

No. It is quoted by slide or case volume, pathologist seats and storage, with the clinically cleared configuration priced separately.

Signant Health: What drives the timeline?

Translation and linguistic validation of outcome instruments, which is per language per instrument and sits on the critical path to study start.

Share

Related pages

More on PathAI

More on Signant Health

Keep looking

Other head to heads